{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-005393","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2023-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.072782+00:00","generated_at":"2026-06-17T07:15:49.816332+00:00","sec_items":["5.02","5.03","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Xilio appoints Kevin Brennan as SVP, Finance and Accounting, principal financial officer","bullets":["Kevin Brennan joined Xilio on March 30, 2023 as SVP, Finance and Accounting and principal financial/accounting officer.","Brennan receives annual base salary of $370,000, target bonus of 35% of base salary.","Granted stock option to purchase 55,000 shares; vests 25% on first anniversary, 75% monthly over 3 years.","Board adopted amended and restated bylaws updating stockholder meeting procedures and universal proxy rules.","Bylaw amendments also include enhanced advance notice disclosure requirements and technical changes."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-005393","json":"https://secwatch.observer/filing/0001558370-23-005393.json","markdown":"https://secwatch.observer/filing/0001558370-23-005393.md","text":"https://secwatch.observer/filing/0001558370-23-005393.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023005393/0001558370-23-005393-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023005393/xlo-20230328x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T07:15:49.816332+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b3ae66b470","claim":"Kevin Brennan was appointed as Senior Vice President, Finance and Accounting at Xilio Therapeutics, Inc..","evidence_excerpt":"On March 30, 2023, Kevin Brennan joined Xilio Therapeutics, Inc. (the “Company”) as Senior Vice President, Finance and Accounting, and the board of directors (the “Board”) of the Company appointed Mr. Brennan to serve as the Company’s principal financial officer and principal accounting officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023005393/0001558370-23-005393-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Senior Vice President, Finance and Accounting"}],"fact_type":"executive_change"},{"claim_id":"3b9ff6220ce37a754f771ba960874cdb68a29443","claim":"Xilio Therapeutics, Inc.: Adopted Second Amended and Restated Bylaws to amend stockholder meeting procedures, voting list requirements, adjournment procedures, advance notice requirements, proxy card color, eliminate director compensation provision, and make technical and conforming changes (effective 2023-03-28).","evidence_excerpt":"On March 28, 2023, the Board adopted amended and restated bylaws of the Company (as amended and restated, the “Second Amended and Restated Bylaws”), effective immediately","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023005393/0001558370-23-005393-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-03-28"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}